DAX24.217 +1,0%ESt505.379 +0,8%Top 10 Crypto15,90 -2,0%Dow44.633 -0,5%Nas21.098 -0,4%Bitcoin102.006 +0,3%Euro1,1550 ±0,0%Öl72,76 +3,4%Gold3.328 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 Rheinmetall 703000 Heidelberger Druckmaschinen 731400 RENK RENK73 Lufthansa 823212 Volkswagen (VW) vz. 766403 Tesla A1CX3T PayPal A14R7U Deutsche Bank 514000 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 DroneShield A2DMAA Amazon 906866 HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt deutlich im Plus -- Wall Street beendet Handel tiefer -- PayPal mit starkem Ergebnis -- D-Wave, Novo Nordisk, Uniper, UnitedHealth, HeidelDruck, TeamViewer, Hypoport, Tilray im Fokus
Top News
BioNTech-Aktie gibt nach: Partnerschaft mit Bristol Myers Squibb zur Fokussierung auf Krebsforschung BioNTech-Aktie gibt nach: Partnerschaft mit Bristol Myers Squibb zur Fokussierung auf Krebsforschung
Tilray-Aktie gibt kräftig nach: Tilray schockiert Anleger mit deutlich höherem Verlust Tilray-Aktie gibt kräftig nach: Tilray schockiert Anleger mit deutlich höherem Verlust
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Jazz Pharmaceuticals Aktie

Handeln
Aktien-Sparplan anlegen
100,75 EUR -0,35 EUR -0,35 %
BMN
116,58 USD -0,84 USD -0,72 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.6,15 Mrd. EUR

KGV14,24Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JS1K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B4Q5ZN47

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJAZZ

Jazz Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireJazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
PR NewswireJazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
PR NewswireJazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Wer­bungJazz Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireJazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
PR NewswireJazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR NewswireZepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
PR NewswireJazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
PR NewswireJazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell ...
PR NewswireJazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ...
PR NewswireJazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated ...
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR NewswireJazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR NewswireJazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Aca...
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Societ...
PR NewswireJazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
PR NewswireJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Jazz Pharmaceuticals News

Jazz Pharmaceuticals News: auf dieser Seite finden Sie alle Jazz Pharmaceuticals News und Nachrichten zur Jazz Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Jazz Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Jazz Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.